[EN] SULFONIMIDAMIDE COMPOUNDS AS NLRP3 MODULATORS<br/>[FR] COMPOSÉS DE SULFONIMIDAMIDE EN TANT QUE MODULATEURS DE NLRP3
申请人:GENENTECH INC
公开号:WO2021150574A1
公开(公告)日:2021-07-29
Described herein are compounds of Formula (I), Formula (I-A), and Formula (I-B), solvates thereof, tautomers thereof, and pharmaceutically acceptable salts of the foregoing, Further described herein are methods of inhibiting NLRP3 using said compounds, and methods of and compositions useful in treating NLRP3-dependent disorders.
Synthesis of diazirinyl organo-platinum complexes, which specifically interact with purine base, characterization of photoreactivity and interaction between guanosine 5′-monophosphate (GMP) were examined. The results indicated that the diazirinyl organo-platinum complex was useful for manipulations of photoaffinity labeled components.
Synthesis and pharmacological characterization of constrained analogues of Vestipitant as in vitro potent and orally active NK1 receptor antagonists
作者:Fabio M. Sabbatini、Romano Di Fabio、Cristiana Griffante、Giorgio Pentassuglia、Laura Zonzini、Sergio Melotto、Giuseppe Alvaro、Anna M. Capelli、Lara Pippo、Elisabetta Perdona’、Yves St. Denis、Silvano Costa、Mauro Corsi
DOI:10.1016/j.bmcl.2009.11.078
日期:2010.1
A focused exploration targeting conformationally restricted analogues of Vestipitant, resulted in the discovery of novel, in vitro potent NK1 antagonists. In particular, two of the compounds reported exhibited a good pharmacokinetic (PK) profile and produced anxiolytic-like effects in the gerbil foot tapping (GFT) in vivo model. (C) 2009 Elsevier Ltd. All rights reserved.